Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
T Cell Non-Hodgkin Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (1034
)
Diffuse Large B Cell Lymphoma (374
)
Mantle Cell Lymphoma (124
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Marginal Zone Lymphoma (40
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (18
)
Mediastinal B Cell Lymphoma (10
)
Non-Hodgkin’s Lymphoma (1034
)
Diffuse Large B Cell Lymphoma (374
)
Mantle Cell Lymphoma (124
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Marginal Zone Lymphoma (40
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (18
)
Mediastinal B Cell Lymphoma (10
)
›
Associations
(117)
News
Trials
Search handles
@ARampotas
@AaronGoodman33
@BijoyTelivala
@BldCancerDoc
@CwynKate
@DrMiguelPerales
@DrRaulCordoba
@DrSteveMartin
@Dr_Daniel_Molin
@Fer_martinmoro
@GuiperiniMD
@HadidiSamer
@JohnPLeonardMD
@MediHumdani
@dgermain21
@doctorpemm
@fdezdelarrea
@graham74GC
@hematologo
@j_marquet
@majorajay
@smbenlazar
@timfenske
@weldeiry
Search handles
@ARampotas
@AaronGoodman33
@BijoyTelivala
@BldCancerDoc
@CwynKate
@DrMiguelPerales
@DrRaulCordoba
@DrSteveMartin
@Dr_Daniel_Molin
@Fer_martinmoro
@GuiperiniMD
@HadidiSamer
@JohnPLeonardMD
@MediHumdani
@dgermain21
@doctorpemm
@fdezdelarrea
@graham74GC
@hematologo
@j_marquet
@majorajay
@smbenlazar
@timfenske
@weldeiry
Filter by
Latest
9ms
@DrKrinaPatel is multi talented, now running a session on lymphoma CAR-T and presented some promising data on CD70 allo CAR-T in T cell lymphoma. This target may be used in #mmsm in future Hard disease and 2 pts cases with early promising results @DAVAOnc #DAVABermudaHeme (@HadidiSamer)
9 months ago
Clinical
|
CD70 (CD70 Molecule)
9ms
Diagnosis of enteropathy-associated T-cell lymphoma (EATL) on peripheral blood: A pleiomorphic morphology and an unusual immunophenotype https://t.co/q4bYOKUrUq #EATL #lymsm @draevens (@e_JHaem)
9 months ago
9ms
Dr. @ravivij Discussing with @NehaMehtaShahMD on #pheripheral #tcell #lymphoma (PTCL) at @My_Cancer_Haven Thank You So much for your support @NehaMehtaShahMD 😊🙏 Get Full Access to the Video, by Signing Up at https://t.co/XIinFH8pLB https://t.co/nnm8ehgnlj (@My_Cancer_Haven)
9 months ago
Video
9ms
Further research projects and Clinical Trials are needed to evaluate the safety and the efficacy of the CAR 7 T cells if would it be applicable on T cell lymphoma as if it is in T Cell ALL published in New England Journal of Medicine June 2023 (@Rashed_AlBakr)
9 months ago
Clinical
10ms
intravascular T cell lymphoma (@mohant73870)
10 months ago
10ms
Our latest study on lncRNA MTAAT deregulation in T-cell Lymphoma is published in @Haematologica! Great collaborations @WeillCornell @FrancescaSangue @StefanoLuminari @CemTameni @UniperugiaNews @MarcoTigano Many thanks to @AIRC_it, AIACE and @Ausl_RE. https://t.co/xY7DHkKzAB (@lab_tres)
10 months ago
10ms
The CAR T-cell therapy AUTO4 was not associated with dose-limiting toxicities and led to early indications of efficacy in patients with relapsed/refractory TRBC1-positive peripheral T-cell lymphoma. @CwynKate @uclh @icmlugano #ICML17 #lymsm #oncology https://t.co/NG8LThxMqe (@OncLive)
10 months ago
Clinical • CAR T-Cell Therapy
|
AUTO4
10ms
Have you ever treated a patient with hepatosplenic t cell lymphoma @AaronGoodman33? My 23 yr old son has crohn's disease & is being managed with azathioprine. He was diagnosed 13 yrs ago. I note his cohort is over-represented in the HSTCL population. (@pauliec80859931)
10 months ago
Clinical
10ms
Findings from the AUTO4-TL1 trial demonstrated that AUTO4 showed early clinical activity and tolerability in relapsed/refractory TRBC1-positive peripheral T-cell lymphoma. @CwynKate @uclh @icmlugano #ICML17 #lymsm #oncology https://t.co/witNC7xJW1 (@OncLive)
10 months ago
Clinical
|
AUTO4
10ms
During the Hidradenitis Suppurativa Workgroup update, @_AprilArmstrong moderated reports on Itch, Cutaneous T-Cell Lymphoma, and #Geriatric Dermatology. Contact @DanielButlerMD to join a new task force, Aging and Geriatric Evaluation in #Dermatology (AGED)! #IDEOM2023 (4/9) (@Dermoutcomes)
10 months ago
10ms
Duvelisib led to a high response rate in patients w/ peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma. @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/v5J1uSXhsl (@OncLive)
10 months ago
Clinical
|
Copiktra (duvelisib)
10ms
Duvelisib led to a high response rate in patients w/ peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma. @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/TJCxD8CBUh (@OncLive)
10 months ago
Clinical
|
Copiktra (duvelisib)
10ms
Some sort of cutaneous T-cell lymphoma? (@jacobmshaner)
10 months ago
10ms
Update of #AUTO4 from @CwynKate, TRBC1 targetting CAR-T for T cell lymphoma. Bench to bedside translational science @uclcancer @uclh @paulmaciocia (@SatyenGohil)
10 months ago
AUTO4
10ms
Duvelisib Demonstrates Higher Activity in Angioimmunoblastic Peripheral T-Cell Lymphoma @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/vb4qA0I7UF (@OncLive)
10 months ago
Copiktra (duvelisib)
10ms
#17ICML E Julia highlights the global reclassification rate after expert pathologist review. It can rise up to 30% in T-cell lymphoma #lymsm (@DrRaulCordoba)
10 months ago
Review
10ms
#17ICML . We are gonna start with challenge cases Hodgkin lymphoma and T-cell lymphoma (@hematologo)
10 months ago
Clinical
11ms
How to treat Peripheral T-cell lymphoma. Feat; PL Zinzani @icmlugano #ICML2023 (@j_marquet)
11 months ago
11ms
Educational session about current and future directions in peripheral T-cell lymphomas therapeutic approach By prof PL Zinzani #17ICML (@Fer_martinmoro)
11 months ago
11ms
Further highlighting the regulatory challenges specific to a rare disease like T-cell lymphoma This table compares the regulatory approvals across different jurisdictions - all over the place!! #17ICML @NehaMehtaShahMD @AdamR_PhD @leah_rand (@Eddie_Cliff)
11 months ago
11ms
Zinzani: periph T-cell Lymphoma. -Treat acc to histology? Some subtypes spec treatm. ECHELON2 (BV-CHP) for CD30+ (spec ALCL) still only pos phase III. -ASCT primary necessary? Seems to add to results. -New drugs in r/r. Unmet needs. #17ICML (@Dr_Daniel_Molin)
11 months ago
P3 data
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
11ms
Fascinating to see efficacy of X+CHOP paradigms in the T-cell lymphoma space. Dr. Zinzani calls attention to both aza and alemtuzumab combinations with high response rates. #lymsm #17ICML cc @BradHaverkos @icmlugano (@majorajay)
11 months ago
Clinical
|
Campath (alemtuzumab)
11ms
@CwynKate your Abstract has been posted online FIRST IN HUMAN STUDY OF AUTO4, A TRBC1-TRAGETTING CART T CELL THERAPY IN RELAPSED/REFRACTORY TRBC1-POSITIVE PERIPHERAL T-CELL LYMPHOMA https://t.co/39iw2Q56AN (@DmitryKovalchuk)
11 months ago
AUTO4
11ms
Abstract for @icmlugano from @CwynKate on the clinical response to AUTO4 from Autolus, targeting T cell lymphoma. Promising Phase I safety data and CMR in 2/4 patients w/ highest dose at 12 and 15 months! https://t.co/JYDm9zRAR5 (@CellTherapyUK)
11 months ago
Clinical
|
AUTO4
11ms
The main on-target s/e with CD19 CAR-Ts is B cell aplasia, which is manageable. With T cell lymphoma, all T cells cannot be targeted (would be life threatening) which is the rationale for AUTO4 (Autolus) that targets TRBC1, leaving healthy TRBC2 T cells remaining. Smart $AUTL (@CellTherapyUK)
11 months ago
Clinical
|
AUTO4
11ms
Promising Ph I safety data & CMR in 2/4 patients w/ highest dose at 12 & 15 months. With T cell lymphoma, pan-T cells Ags can’t be targeted (toxicity) thus rationale for AUTO4 targeting TRBC1, so healthy TRBC2 T cells remain (no ⬆️infectious tox observed to date) #17ICML #lymsm (@CwynKate)
11 months ago
Clinical
|
AUTO4
11ms
EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA #EHA23 (@smbenlazar)
11 months ago
Clinical
11ms
ALLOGENEIC STEM CELL TRANSPLANTATION FOR NK/T-CELL LYMPHOMA IN THE ERA OF ASPARAGINASE-BASED CHEMOTHERAPY #EHA23 (@smbenlazar)
11 months ago
11ms
Attending #EHA2023 virtually: 3/5 oral abstracts in ‘Lymphoma biology & translational studies’ session focused on #T-cell lymphoma Sunday 11 June 11:30-12:45 CEST & Lymphoid Biology and Malignancy Workshop: T follicular helper cells from biology to neoplasia 👏 @EHA_Hematology (@CwynKate)
11 months ago
11ms
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) Havcr2 gene. skin lymphoma that is localized to the subcutaneous adipose tissue no lymph nodes involve Tx. systemic steroids or immunosuppressive such as etoposide, cyclosporine A, methotrexate, chlorambucil, and bexarotene (@DrZahidHussain3)
11 months ago
HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
etoposide IV • methotrexate • Leukeran (chlorambucil) • Targretin oral (bexarotene oral)
11ms
"A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant" At #ASCO23 from 2 @WUHemeOncFellow --Niki Foley and soon-to-be @WashUOnc faculty @dgermain21 #lymsm https://t.co/y4Bcx859ZP (@WashUOnc)
11 months ago
Clinical • Minimal residual disease
11ms
Extranodal NK/T-cell lymphoma, nasal subtype #entpath #hemepath @smlungpathguy @SocforHemepath @ENT_Path @IHC_guy @hematogones @UFCSPA_patho @TristanRutland7 @JMGardnerMD @Sara_Jiang @01sth02 (@pbaleixo)
11 months ago
12ms
Cantor #Biotechs Cantor Hosting:Virtual KOL Call discuss Key Takeaways #EHA23 June 12 11AM ET •Menin inhibitor space $KURA $SNDX $APTO tuspetinib for FLT3m, FLT3- Therapies for T-cell lymphomas: $AFMD innate cell engager AFM13 mono + NK-cell combo, $CRVS ITK-inhibitor CPI-818 (@semodough)
12 months ago
acimtamig (AFM13) • tuspetinib (HM43239) • soquelitinib (CPI-818)
12ms
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma #tcellrx #CellTherapy #lymsm @BloodJournal https://t.co/CuZlYI9UlX (@BldCancerDoc)
12 months ago
Yescarta (axicabtagene ciloleucel)
12ms
1/2 Malignancy highly likely causes could be ⏺️Nasopharyngeal carcinoma ⏺️Nasal NK/T cell lymphoma ⏺Burkitt lymphoma ⏺️Rhabdomyosarcoma Non-malignant causes ⏺️ Fungal ( Mucor/Fusarium/Aspergillus) ⏺️Nasopharyngeal Angiofibroma ⏺️ Hemangioma (@Satyayadav__)
12 months ago
12ms
Approaches to Upfront Therapy in T-cell Lymphoma by @NehaMehtaShahMD (@arivasdelgado)
12 months ago
12ms
Researchers including @WCMEnglanderIPM and Dir. @ElementoLab, @WCM_MeyerCancer, @WCMLymphoma, @JohnPLeonardMD, find "Adding Epigenetic Drug to Standard #Chemotherapy Was Effective in Pilot Study for T-cell #Lymphoma," @BloodJournal. [Photo: Shutterstock] https://t.co/0WBBaJTLr3 (@WCMEnglanderIPM)
12 months ago
Clinical
|
TLR3 (Toll Like Receptor 3)
1year
Germline HAVCR2 mutations and their relation to the clinical spectrum of subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis: results from a multicenter study and meta-analysis Early View @Haematologica https://t.co/UZKKbaoFJQ (@CwynKate)
1 year ago
Retrospective data
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
1year
New from @PennMedicine: “Identifying highly active anti-CCR4-CAR T cells for the treatment of T-cell lymphoma” in Blood Advances @carlhjune https://t.co/s0xrDyvfXs (@IAmDrDex)
1 year ago
CAR T-Cell Therapy
|
CCR4 (C-C Motif Chemokine Receptor 4)
1year
Super wonderful talk by Dr Swami Iyer @DrSwami_Iyer at #DAVAWhistler heme summit meeting !! #CD70 CART in T-cell lymphomas @DAVAOnc 👏🏽 (@doctorpemm)
1 year ago
CD70 (CD70 Molecule)
1year
Dr Cooper: lymphoma in the liver 🟣12% T cell 🔵Patterns: portal predominate, sinusoidal, lobular aggregates, or mixed ⚪️Can include TCL NOS, extranodal T cell, hepatosplenic T cell lymphoma #USCAP2023 (@liverpath)
1 year ago
SKAP2 (Src Kinase Associated Phosphoprotein 2)
1year
#PrescientTherapeutics receives #FDA #OrphanDrug status for #PTX100 to treat #Tcelllymphomas https://t.co/dohXlrSUWj (@1stOncology)
1 year ago
Orphan drug
|
PRDX2 (Peroxiredoxin 2)
|
PTX-100
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login